Morgan Stanley
MS
$222.28
+0.07%
Morgan Stanley is a global financial services firm providing investment banking, wealth management, and asset management services across 42 countries. It is a top-tier player in capital markets, with a dominant wealth management franchise boasting $9.3 trillion in client assets and a top-10 U.S. banking operation by deposits. The current investor narrative centers on the rebound in investment banking fees, driven by a resurgent IPO market (e.g., SpaceX) and M&A activity, alongside the firm's strategic shift toward stable wealth management revenues. Recent stress test success and capital return announcements have also fueled optimism, though valuation concerns and sector downgrades ahead of Q2 earnings introduce debate.…
MS
Morgan Stanley
$222.28
Related headlines
Investment Opinion: Should I buy MS Today?
Rating: Buy. Thesis: Morgan Stanley offers a compelling risk/reward with accelerating revenue growth, expanding margins, and a low PEG ratio, supported by a rebound in investment banking fees and strong capital return prospects. The analyst consensus is bullish with an implied average target of ~$269.70, representing +21.3% upside.
Supporting Evidence: (1) Revenue grew 11.1% YoY in Q4 2025 to $28.86B, accelerating from 6.9% in Q3. (2) Operating margin expanded to 20.0% from 18.9% YoY, and net margin improved to 15.2% from 14.3%. (3) PEG ratio of 0.60x indicates undervaluation relative to earnings growth. (4) ROE of 15.1% is strong and above the industry average of ~12%. (5) The implied forward P/E of 14.1x based on estimated EPS of $15.81 offers a discount to the trailing P/E of 17.17x, suggesting upside if growth materializes.
Risks & Conditions: The biggest risks are a slowdown in investment banking revenue growth, valuation compression if the market re-rates the sector, and negative free cash flow. This Buy rating would be downgraded to Hold if revenue growth decelerates below 8% YoY or if the P/E exceeds 20x without corresponding earnings acceleration. It would be upgraded if the stock pulls back to a P/E below 15x or if the SpaceX IPO and other deals drive a sustained fee rebound. Overall, MS appears fairly valued relative to its history (P/E range 8.5x-24.7x) but slightly overvalued vs. sector peers. The growth trajectory and PEG ratio support a Buy for investors with a 12-month horizon.
Sign up to view all
MS 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Morgan Stanley's strong revenue growth, expanding margins, and low PEG ratio support a positive outlook. The analyst consensus and recent catalysts like the SpaceX IPO reinforce the bull case. However, the elevated valuation relative to peers and sector downgrade risks temper confidence. The base case of 10-12% revenue growth and a target of $240-270 is most likely. An upgrade to high confidence would require sustained revenue growth above 15% and margin expansion, while a downgrade would occur if growth decelerates below 8% or if the stock fails to hold above $200.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Morgan Stanley's 12-month outlook, with a consensus price target around $288.96 and implied upside of +30.0% versus the current price.
Average Target
$288.96
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$178 - $289
Analyst target range
Seven analysts cover Morgan Stanley, with a consensus leaning bullish. Ratings include multiple Outperform and Overweight ratings from firms like Keefe, Bruyette & Woods, Barclays, and Wolfe Research, with no Sell ratings observed. The average EPS estimate for the next fiscal year is $15.81, with a low of $15.01 and high of $16.74. Using the current price of $222.28 and the average EPS estimate, the implied forward P/E is 14.1x, suggesting upside if the market re-rates. The average target price is not directly provided, but based on the forward P/E of 17.06x (from valuation data) and estimated EPS of $15.81, the implied target is approximately $269.70, representing +21.3% upside. The high target (assuming 17x on high EPS of $16.74) would be ~$284.58, while the low target (17x on low EPS of $15.01) would be ~$255.17. The spread between high and low is about 11.5%, indicating moderate uncertainty. Recent analyst actions show upgrades (Wolfe Research from Peer Perform to Outperform in Nov 2025) and reiterations of positive ratings, reinforcing bullish sentiment. The wide range reflects differing views on the sustainability of investment banking revenue growth and potential margin pressures.
Bulls vs Bears: MS Investment Factors
Morgan Stanley presents a balanced risk/reward profile. On the bull side, strong revenue growth acceleration (11.1% YoY), expanding margins, a low PEG ratio (0.60x), and bullish analyst consensus with 21.3% upside support a positive view. However, bears point to elevated valuation (P/E 17.17x vs. sector 15x), high leverage (D/E 4.26), negative FCF, and sector downgrade risks. The single most important tension is whether the rebound in investment banking fees (driven by IPOs like SpaceX and M&A) can sustain revenue growth above 10% and justify the premium valuation. If growth decelerates, the stock could re-rate lower; if it accelerates, the PEG ratio suggests further upside. Currently, the bull case has slightly stronger evidence given the growth momentum and analyst support, but the valuation leaves little margin of safety.
Bullish
- Strong Revenue Growth Acceleration: Revenue grew 11.1% YoY in Q4 2025 to $28.86B, accelerating from 6.9% in the prior quarter, driven by a rebound in investment banking fees and steady wealth management revenues.
- Expanding Profit Margins: Operating margin improved to 20.0% in Q4 2025 from 18.9% a year ago, while net margin rose to 15.2% from 14.3%, reflecting operating leverage and cost discipline.
- Attractive PEG Ratio of 0.60x: With a PEG ratio of 0.60x, the stock is undervalued relative to its earnings growth rate, suggesting that the market is not fully pricing in the growth trajectory.
- Strong Capital Return Catalyst: After passing Fed stress tests, Morgan Stanley is expected to increase dividends and buybacks, with a current payout ratio of 39.1% and dividend yield of 2.36%, providing shareholder returns.
Bearish
- Elevated Valuation vs. Peers: Trailing P/E of 17.17x is at a ~14% premium to the S&P 500 financial sector average of ~15x, and above the capital markets industry average of 12-15x, leaving limited room for multiple expansion.
- High Financial Leverage: Debt-to-equity of 4.26x and total debt to capitalization of 80.9% are typical for banks but expose the firm to higher interest expense and credit risk, especially if the economy slows.
- Negative Free Cash Flow: TTM free cash flow is -$17.89B, largely due to working capital swings from trading activities, which could pressure liquidity or force reliance on external financing.
- Sector Downgrade Risk Ahead of Q2 Earnings: Recent news highlights a downgrade wave for bank stocks as valuations peak, with analysts recommending rotation into super-regional banks and alternative asset managers, potentially dampening sentiment.
MS Technical Analysis
Morgan Stanley is in a sustained uptrend, with the stock up 55.3% over the past year, significantly outperforming the S&P 500's 20.6% gain. The current price of $222.28 sits at 96.5% of its 52-week range ($135.26–$230.47), indicating the stock is near its highs and reflecting strong momentum. This positioning suggests the market is pricing in continued positive catalysts, but also raises the risk of overextension. Short-term momentum is accelerating: the 1-month change is +7.6% and the 3-month change is +25.1%, both outpacing the S&P 500's respective gains of 4.1% and 11.1%. The relative strength over 1 month is 3.5%, confirming near-term outperformance. This acceleration aligns with the longer-term uptrend, reinforcing bullish sentiment. The 52-week high of $230.47 acts as immediate resistance; a breakout above this level would signal further upside and likely attract momentum buyers. Support lies near the 52-week low of $135.26, though the stock has not tested that level in months. With a beta of 1.22, MS is 22% more volatile than the market, meaning it amplifies both gains and losses, which is important for risk management.
Beta
1.22
1.22x market volatility
Max Drawdown
-19.3%
Largest decline past year
52-Week Range
$135-$230
Price range past year
Annual Return
+55.3%
Cumulative gain past year
| Period | MS Return | S&P 500 |
|---|---|---|
| 1m | +7.6% | +1.8% |
| 3m | +25.1% | +10.0% |
| 6m | +19.3% | +8.8% |
| 1y | +55.3% | +21.1% |
| ytd | +22.2% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MS Fundamental Analysis
Revenue is growing robustly: the most recent quarter (Q4 2025) reported $28.86 billion, up 11.1% year-over-year from $25.98 billion in Q4 2024. This marks an acceleration from the prior quarter's 6.9% YoY growth, driven by a rebound in investment banking fees (Institutional Securities segment contributed $7.93 billion) and steady wealth management revenues ($8.43 billion). The multi-quarter trend shows revenue rising from $25.35 billion in Q1 2024 to $28.86 billion in Q4 2025, indicating a clear growth trajectory. Profitability is solid: net income for Q4 2025 was $4.40 billion, with a net margin of 15.2%. Gross margin improved to 58.0% from 57.5% a year ago, while operating margin expanded to 20.0% from 18.9%, reflecting operating leverage. The company is consistently profitable, with EPS of $2.71 in Q4 2025 versus $2.25 in Q4 2024, a 20.4% increase. The balance sheet shows high leverage: debt-to-equity is 4.26, and total debt to capitalization is 80.9%, typical for a bank. However, free cash flow is negative on a TTM basis at -$17.89 billion, largely due to working capital swings from trading activities. The company holds $111.7 billion in cash, providing ample liquidity. ROE is 15.1%, indicating strong returns on equity capital.
Quarterly Revenue
$28.9B
2025-12
Revenue YoY Growth
+11.08%
YoY Comparison
Gross Margin
58.02%
Latest Quarter
Free Cash Flow
$-17.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MS Overvalued?
Since net income is positive, we lead with the P/E ratio. The trailing P/E is 17.17x, while the forward P/E is 17.06x, implying minimal growth expectations priced in for the next year. The gap between trailing and forward is negligible, suggesting the market expects earnings to remain stable. Compared to the industry average (not explicitly provided, but capital markets firms typically trade at 12-15x), MS's P/E of 17.17x appears at a premium. For context, the S&P 500 financial sector P/E is around 15x, so MS trades at a roughly 14% premium. This premium may be justified by its superior wealth management franchise and higher ROE (15.1% vs. industry average ~12%). Historically, MS's trailing P/E has ranged from 8.5x (Q1 2021) to 24.7x (Q4 2023). The current 17.17x is near the middle of this range, suggesting the stock is fairly valued relative to its own history. The PEG ratio of 0.60x indicates the stock is undervalued relative to its earnings growth rate, supporting a bullish view.
PE
17.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Morgan Stanley's high debt-to-equity ratio of 4.26x and total debt to capitalization of 80.9% indicate significant financial leverage, which amplifies earnings volatility and interest expense sensitivity. The TTM free cash flow of -$17.89B is a concern, as it stems from working capital swings in trading activities, potentially requiring external financing or asset sales to cover cash needs. Net margin of 15.2% is solid but could compress if investment banking revenues normalize or if credit losses rise. The reliance on investment banking fees (Institutional Securities segment contributed $7.93B in Q4) introduces earnings cyclicality, as a slowdown in M&A or IPO activity could pressure profitability.
Market & Competitive Risks: The stock's beta of 1.22 indicates 22% higher volatility than the market, making it sensitive to macro shocks and sector rotation. At a trailing P/E of 17.17x, MS trades at a premium to the S&P 500 financial sector average of ~15x, leaving it vulnerable to valuation compression if growth disappoints. Recent news highlights a downgrade wave for large-cap bank stocks ahead of Q2 earnings, with analysts citing peak valuations and recommending rotation into super-regionals. Additionally, regulatory changes or a downturn in capital markets activity could reduce fee income. The competitive landscape includes Goldman Sachs and JPMorgan, which also benefit from the same IPO and M&A tailwinds, limiting MS's unique advantage.
Worst-Case Scenario: In a severe recession or prolonged market downturn, investment banking fees could collapse, wealth management revenues could decline on lower asset values, and credit losses could spike. Given the high leverage, earnings could fall sharply, leading to a re-rating of the stock. The 52-week low of $135.26 represents a potential downside of -39% from the current price of $222.28. Historical max drawdown of -19.28% (from recent data) suggests a more moderate risk, but the worst-case scenario could approach the 52-week low if the economy enters a deep recession and the IPO market freezes.
FAQ
The key risks are: (1) Financial leverage risk: Debt-to-equity of 4.26x amplifies earnings volatility and interest expense sensitivity. (2) Cyclical revenue risk: Investment banking fees are tied to IPO and M&A activity, which can decline sharply in a downturn. (3) Valuation risk: The P/E of 17.17x is above the sector average, leaving room for multiple compression if growth disappoints. (4) Negative free cash flow: TTM FCF of -$17.89B could pressure liquidity. The most severe risk is a recession that cuts fee income and increases credit losses, potentially driving the stock down 39% to the 52-week low of $135.26.
The 12-month forecast is moderately bullish. The base case (50% probability) expects revenue growth of 10-12% YoY, with the stock trading near the analyst average target of ~$269.70, implying +21.3% upside. The bull case (30% probability) sees a surge in investment banking fees from IPOs like SpaceX, pushing the stock to $255-285. The bear case (20% probability) involves a macro downturn that reduces fee income, with the stock falling to $170-210. The most likely scenario is the base case, driven by a continued rebound in capital markets activity and steady wealth management growth.
MS stock appears fairly valued relative to its own history but slightly overvalued compared to sector peers. The trailing P/E of 17.17x is within the historical range of 8.5x to 24.7x, near the midpoint, suggesting fair value. However, it trades at a ~14% premium to the S&P 500 financial sector average of 15x. The PEG ratio of 0.60x indicates undervaluation relative to its earnings growth rate, implying the market is not fully pricing in the growth trajectory. The forward P/E of 17.06x is nearly identical to the trailing, suggesting minimal growth expectations for the next year. Overall, the valuation is reasonable for a high-quality franchise with a 15.1% ROE, but there is limited margin of safety.
Yes, MS is a good stock to buy for investors with a 12-month horizon, given the strong revenue growth (11.1% YoY), expanding margins, and a low PEG ratio of 0.60x indicating undervaluation relative to earnings growth. The analyst consensus is bullish with an implied average target of ~$269.70, offering +21.3% upside from the current price of $222.28. However, the stock trades at a premium P/E of 17.17x vs. the financial sector average of 15x, so it is not a deep value play. The biggest downside risk is a slowdown in investment banking fees or a macro downturn that could push the stock toward the 52-week low of $135.26. For growth-oriented investors comfortable with cyclicality, MS is a buy; for conservative investors, it may be better to wait for a pullback.
MS is suitable for both short-term and long-term investment, but it is better aligned with a medium-to-long-term horizon of 12-24 months. The stock's beta of 1.22 makes it more volatile than the market, offering short-term trading opportunities around earnings and IPO catalysts. However, the cyclical nature of investment banking revenues means that long-term investors must be comfortable with earnings fluctuations. The dividend yield of 2.36% and strong capital return program provide some income, but the primary return driver is capital appreciation. A minimum holding period of 12 months is recommended to capture the expected rebound in fee income and allow the valuation to re-rate.